Christopher J Coughlin's Insider Trades & SAST Disclosures
Christopher J Coughlin's most recent trade in Centene Corp. was a trade of 497 Common Stock done . Disclosure was reported to the exchange on Dec. 31, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher J Coughlin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 497 | 6,800 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Purchase of securities on an exchange or from another person at price $ 59.44 per share. | 16 Dec 2024 | 10,000 | 36,357 (0%) | 0% | 59.4 | 594,400 | Common Stock |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 402 | 26,357 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2024 | 452 | 25,955 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 2,916 | 25,503 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Sale of securities on an exchange or to another person at price $ 76.74 per share. | 14 May 2024 | 878 | 0 (0%) | 0% | 76.7 | 67,382 | Common Stock |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 388 | 22,587 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Coughlin Christopher J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 502 | 22,199 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2023 | 544 | 21,696 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 543 | 21,152 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 1,904 | 1,904 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 990 | 990 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 2,947 | 20,608 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 510 | 17,661 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 407 | 407 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 321 | 321 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 181 | 181 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 67 | 67 | - | - | Option (right to buy) | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 443 | 17,150 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 405 | 16,707 (0%) | 0% | 0 | Common Stock | |
| Prestige Consumer Healthca... | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2022 | 2,495 | 13,218 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 436 | 16,301 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 5,000 | - | - | Option (right to buy) | |
| Centene Corp. | Christopher J. Coughlin | Director | Purchase of securities on an exchange or from another person at price $ 81.37 per share. | 29 Apr 2022 | 12,000 | 15,864 (0%) | 0% | 81.4 | 976,440 | Common Stock |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 2,323 | 3,864 (0%) | 0% | 0 | Common Stock | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 82.20 per share. | 31 Mar 2022 | 441 | 1,541 (0%) | 0% | 82.2 | 36,250 | Common Stock |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 10,000 | 10,000 | - | - | Common Stock Option (right to buy) | |
| Centene Corp. | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 1,100 | 1,100 (0%) | 0% | 0 | Common Stock | |
| Prestige Consumer Healthca... | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 2,808 | 10,723 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 8,500 | 8,500 | - | - | Option (right to buy) | |
| Prestige Consumer Healthca... | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2020 | 3,732 | 7,915 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Karuna Therapeutics Inc | Christopher J. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 25,000 | 25,000 | - | - | Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges